| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 08/06/2024 | 02:04 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:APGE | Apogee Therapeutics Inc |
| 07/06/2024 | 22:02 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:APGE | Apogee Therapeutics Inc |
| 31/05/2024 | 02:05 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:APGE | Apogee Therapeutics Inc |
| 28/05/2024 | 13:36 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material | NASDAQ:APGE | Apogee Therapeutics Inc |
| 28/05/2024 | 13:30 | GlobeNewswire Inc. | Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD | NASDAQ:APGE | Apogee Therapeutics Inc |
| 23/05/2024 | 13:30 | GlobeNewswire Inc. | Apogee Therapeutics to Participate in Upcoming June Investor Conferences | NASDAQ:APGE | Apogee Therapeutics Inc |
| 15/05/2024 | 22:01 | GlobeNewswire Inc. | Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases | NASDAQ:APGE | Apogee Therapeutics Inc |
| 13/05/2024 | 13:26 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:APGE | Apogee Therapeutics Inc |
| 13/05/2024 | 13:10 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:APGE | Apogee Therapeutics Inc |
| 13/05/2024 | 13:00 | GlobeNewswire Inc. | Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results | NASDAQ:APGE | Apogee Therapeutics Inc |
| 06/05/2024 | 14:00 | GlobeNewswire Inc. | Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference | NASDAQ:APGE | Apogee Therapeutics Inc |
| 25/03/2024 | 12:00 | GlobeNewswire Inc. | Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases | NASDAQ:APGE | Apogee Therapeutics Inc |
| 12/03/2024 | 21:01 | GlobeNewswire Inc. | Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million | NASDAQ:APGE | Apogee Therapeutics Inc |
| 11/03/2024 | 11:01 | Edgar (US Regulatory) | Form 424B4 - Prospectus [Rule 424(b)(4)] | NASDAQ:APGE | Apogee Therapeutics Inc |
| 08/03/2024 | 06:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:APGE | Apogee Therapeutics Inc |
| 08/03/2024 | 00:49 | GlobeNewswire Inc. | Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering | NASDAQ:APGE | Apogee Therapeutics Inc |
| 08/03/2024 | 00:27 | Edgar (US Regulatory) | Form S-1MEF - Registration adding securities to prior Form S-1 registration [Rule 462(b)] | NASDAQ:APGE | Apogee Therapeutics Inc |
| 05/03/2024 | 22:23 | GlobeNewswire Inc. | Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering | NASDAQ:APGE | Apogee Therapeutics Inc |
| 05/03/2024 | 22:05 | Edgar (US Regulatory) | Form S-1 - General form for registration of securities under the Securities Act of 1933 | NASDAQ:APGE | Apogee Therapeutics Inc |
| 05/03/2024 | 12:15 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:APGE | Apogee Therapeutics Inc |
| 05/03/2024 | 12:10 | GlobeNewswire Inc. | Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results | NASDAQ:APGE | Apogee Therapeutics Inc |
| 05/03/2024 | 12:00 | GlobeNewswire Inc. | Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of Sch | NASDAQ:APGE | Apogee Therapeutics Inc |
| 04/03/2024 | 22:01 | GlobeNewswire Inc. | Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024 | NASDAQ:APGE | Apogee Therapeutics Inc |
| 02/01/2024 | 13:30 | GlobeNewswire Inc. | Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference | NASDAQ:APGE | Apogee Therapeutics Inc |
| 13/11/2023 | 13:30 | GlobeNewswire Inc. | Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial Results | NASDAQ:APGE | Apogee Therapeutics Inc |
| 30/10/2023 | 13:00 | GlobeNewswire Inc. | Apogee Therapeutics to Participate in Upcoming November Investor Conferences | NASDAQ:APGE | Apogee Therapeutics Inc |
| 27/09/2023 | 14:42 | GlobeNewswire Inc. | Apogee Announces Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology (EADV) Congress | NASDAQ:APGE | Apogee Therapeutics Inc |
| 14/09/2023 | 13:30 | GlobeNewswire Inc. | Apogee Therapeutics to Participate at the 2023 Stifel Virtual I&I Day | NASDAQ:APGE | Apogee Therapeutics Inc |
| 29/08/2023 | 14:00 | PR Newswire (US) | Paragon Therapeutics Recognizes Key Milestones and Leadership Appointment for First Spinout, Apogee Therapeutics | NASDAQ:APGE | Apogee Therapeutics Inc |
| 28/08/2023 | 13:30 | GlobeNewswire Inc. | Apogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial Results | NASDAQ:APGE | Apogee Therapeutics Inc |